There is multiple research work going on to develop new ways of preventing cancer, but innovating a way to stop this terrible circumstance through an error is perhaps a big surprise. As per an insight, a group of researchers from Chicago stated that carvedilol, a drug better known to be utilized in curing high blood pressure, can protect against cell damages which are caused by sunbeams. These damaged cells were considered as the primary cause of sun-ray-induced cancer. The team also mentioned that this cancer-preventing property of the beta blocker was discovered by an error in the lab.
According to Eurekalert, Ying Huang, PhD, co-leader of the research team said "What began as an experimental error led to a very interesting scientific discovery," The report suggested that the property was actually innovated when former graduate student in Huang's lab was studying whether carvedilol and similar beta blockers come with the properties to intensify cancer.
In an attempt to check out the promotional context of cancer, he accidentally came out with the cancer debarring attributes of carvedilol. The researchers then tested cancer preventing properties of the beta blocker. They evolved their research on cell cultures and mice to understand whether this beta blocker can protect the skin cells from damages caused by the ultraviolet-B (UVB) rays driven by sunlight.
As per a report by Medical Express, the findings deployed that carvedilol protected the cells against the cancer-causing DNA damage and cell death produced by UVB and thus cultured mouse skins exposed to sunlight. The beta blocker provided on a hairless mouse, which was exposed to UVB, also showcased the decrease in the number of tumors caused by cell damage. Although, beta-blockers other than Carvedilol are still required to be tested on different parameters to rest assured about their cancer-rejecting quality.
The findings of this beta blocker will soon be presented by Sherry Liang, a graduate student at the Western University of Health Sciences College of Pharmacy, at the American Society for Pharmacology and Experimental Therapeutics annual meeting during the Experimental Biology 2017 meeting which is scheduled to be held in Chicago on April 22, 2017 to April 26, 2017. The scientists are also interested in introducing the property of Carvedilol in the form of an ointment soon.
